Autres langues AB Science

Actions

AB

FR0010557264

Produits pharmaceutiques

Marché Fermé - Euronext Paris Autres places de cotation 17:55:00 19/06/2026			Varia. 5j.	Varia. 1 janv.
0,8950 ^EUR	+5,17%		+0,56%	-41,73%

18/06	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
18/06	Star Warsh

Autres langues

18/06	AB Science Secures US Patent for Prostate Cancer Therapy
17/06	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042
09/06	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
02/06	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share
26/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share
25/05	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
18/05	AB Science S.A. announced that it has received $2.989368 million in funding
13/05	AB Science : Annual financial results as of 31 December, 2025
13/05	AB Science reports its revenues for the year 2025 and provides an update on its activities
13/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding
29/04	AB Science announces the successful completion of a EUR 3.2 million private placement
28/04	AB Science Reaches Maturity Extension Deal with Lenders
27/04	AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04	AB Science SA Announces Final Agreement on Renegotiation of Repayment Terms of Loans With Financial Creditors
20/04	AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04	AB Science Announces New Publication Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in Amyotrophic Lateral Sclerosis Patients
16/04	AB Science temporarily halts Europe clinical trials ahead of strategic reorganization
16/04	AB Science provides an update on its clinical development program.
16/04	AB Science Provides Update on Clinical Development Program
24/02	AB Science : annonce l’identification d’un biomarqueur plasmatique marqueur de l’activité du masitinib dans le traitement de la SLA
24/02	AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
24/02	AB Science SA Announces the Identification of A Plasma Biomarker That Indifies the Activity of Masitinib in Amyotrophic Lateral Sclerosis
10/02	AB Science Wins US FDA MUMS Status for Canine Mast Cell Tumors Treatment